About: An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
Creator	Wang, Jian Liu, Jinxin Zhang, Lieguang Li, Feng Hong, Wenxin Zhang, Fuchun Wang, Yaping Deng, Xilong Hu, Fengyu Li, Yueping Wen, Chunyan Cai, Weiping Chen, Xudan Guan, Yujuan Li, Linghua Lin, Weiyin Mo, Xiaoneng Peng, Ping Xiao, Guangming Xie, Zhiwei
Source	MedRxiv
abstract	Background: Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. Methods: Our study (NCT04252885, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19. Findings: This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34 randomly assigned to receive LPV/r, 35 to arbidol and 17 with no antiviral medication as control. Baseline characteristics of the three groups were comparable. The primary endpoints, the average time of positive-to-negative conversion of SARS-CoV-2 nucleic acid and conversion rates at days 7 and 14, were similar between groups (all P>0.05). There were no differences between groups in the secondary endpoints, the rates of antipyresis, cough alleviation, or improvement of chest CT at days 7 or 14 (all P>0.05). At day 7, eight (23.5%) patients in the LPV/r group, 3 (8.6%) in the arbidol group and 2(11.8%) in the control group showed a deterioration in clinical status from moderate to severe/critical(P =0.206). Overall, 12 (35.3%) patients in the LPV/r group and 5 (14.3%) in the arbidol group experienced adverse events during the follow-up period. No apparent adverse event occurred in the control group. Conclusions: LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care.
has issue date	2020-03-23(xsd:dateTime)
bibo:doi	10.1101/2020.03.19.20038984
has license	medrxiv
sha1sum (hex)	02df119c0f91886eccafc4f67d58b17b1b3760dc
schema:url	https://doi.org/10.1101/2020.03.19.20038984
resource representing a document's title	An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
resource representing a document's body	covid:02df119c0f91886eccafc4f67d58b17b1b3760dc#body_text
is schema:about of	named entity 'patients' named entity 'antiviral' named entity 'global pandemic' named entity 'COVID-19' named entity 'arbidol' named entity 'SARS-CoV-2' named entity 'prognosis' named entity 'monotherapy' named entity 'preprint' named entity 'coronavirus' named entity 'peer-reviewed' named entity 'Lopinavir' named entity 'medRxiv' named entity 'preprint' named entity '21 days' named entity 'pharyngeal' named entity '8.5' named entity 'preprint' named entity 'monotherapy' named entity 'adverse event' named entity 'sample size' named entity 'COVID-19' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'arbidol' named entity 'Lopinavir/ritonavir' named entity 'vaccine' named entity 'white blood cell count' named entity 'clinical trial' named entity 'oxygen therapy' named entity 'H1N1' named entity 'control group' named entity 'COVID' named entity 'ECMO' named entity 'phagocytic' named entity 'pathogenesis' named entity 'creatinine' named entity 'ritonavir' named entity 'cough' named entity 'arbidol' named entity 'respiratory failure' named entity 'clinical trials' named entity 'arbidol' named entity 'pneumonitis' named entity 'diarrhea' named entity 'treatment compliance' named entity 'one-way ANOVA' named entity 'Shanghai' named entity 'glucocorticoids' named entity 'host cell' named entity 'cultured cells' named entity 'COVID' named entity 'peer-reviewed' named entity 'COVID' named entity 'medRxiv' named entity 'peer-reviewed' named entity 'arbidol' named entity 'creatinine clearance' named entity 'procalcitonin' named entity 'diabetes' named entity 'diarrhea' named entity 'control group' named entity 'diarrhea' named entity 'loss of appetite' named entity 'kidney disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software